CT-322
Term · Oncology and biomedicine · MLC-T-ONC-002166
A substance being studied in the treatment of cancer. CT-322 may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor and a type of antiangiogenesis agent. Also called Angiocept and VEGFR-2 inhibitor CT-322.
| Identifier | MLC-T-ONC-002166 |
|---|---|
| Field | Oncology and biomedicine |
| Expansions | Angiocept; VEGFR-2 inhibitor CT-322 |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-002166",
"term": "CT-322",
"field": "Oncology and biomedicine",
"definition": "A substance being studied in the treatment of cancer. CT-322 may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor and a type of antiangiogenesis agent. Also called Angiocept and VEGFR-2 inhibitor CT-322.",
"expansions": [
"Angiocept",
"VEGFR-2 inhibitor CT-322"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/ct-322/"
}
Record 5,482 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.